Valid

YY/T 1181-2021Immunohistochemistry kit (English PDF)

免疫组织化学试剂盒

Preview PDF

This is a limited preview

Buy now to download the full PDF (21 pages)

Need quotation for your management?

Get a formal quotation for YY/T 1181-2021 in 30 minutes.

Issued by

NMPA

Level / Type

Industry · Recommended

Issue date

September 6, 2021

Implementation date

March 1, 2023

Scope

YY/T 1181-2021 is the English-translated version of 免疫组织化学试剂盒.

YY/T 1181-2021 is the Chinese pharmaceutical industry standard for immunohistochemistry kits, the reagents that reveal an antigen in a tissue or cell sample through an antigen-antibody reaction.

It sets the classification of the products, the requirements and the test methods, and the rules for identification, labels, instructions for use, packaging, transport and storage.

It applies to qualitative histochemical and cytochemical reagents and kits used on human tissue and cell specimens, the requirements covering appearance, the specificity of the staining, its intensity and the absence of background, the repeatability between runs and the stability of the reagents.

It replaces YY/T 1181-2010, was issued on 6 September 2021 and has applied since 1 March 2023.

Found what you need?

Document preview — YY/T 1181-2021

National Standard of the People's Republic of China

Classification
C 44
Replacing
YY/T 1181-2010

Issued by: National Medical Products Administration of the People's Republic of China

Contents

  • Foreword
  • 1 Scope
  • 2 Normative references
  • 3 Terms and Definitions

Foreword

This standard was drafted in accordance with the rules given in GB/T 1.1-2009.

This standard replaces YY/T 1181-2010 "Immunohistochemistry Kits", compared with YY/T 1181-2010, except for editorial changes The main technical changes are as follows.

---In the scope, the original "this standard applies to the detection of paraffin sections, ice and Tissue/cytochemical qualitative kits for frozen sections, smears, smears and other specimens" was revised to "This standard applies to antigen-antibody-based Reaction, histochemical/cytochemical qualitative reagents or kits for the detection of human tissue and cell samples, etc." (see Chapter 1, Chapter 1 of the.2010 edition);

--- Deleted "The kit includes at least primary antibody and color development system" from the scope (see Chapter 1 of the.2010 edition);

---In the normative reference document "YY/T 0466.1-2009 Medical Devices for Medical Device Labeling, Marking and Providing Information The symbol of Part 1: General requirements" is revised to "GB/T 29791.2 Letters provided by manufacturers of in vitro diagnostic medical devices Information (Marking) Part 2: In Vitro Diagnostic Reagents for Professional Use" (see Chapter 2, Chapter 2 of the.2010 edition);

---Definition "Using the principle of specific binding of antigens and antibodies, the chromogenic substances (fluorescein, fluorescein, Enzymes, metal ions, isotopes) color development to detect tissue cell antigens, localization, qualitative and quantitative detection technology" Changed to "Using the principle of specific binding of antigen and antibody, through chemical reaction, the chromogenic substance (fluorescein, fluorescein, Enzymes, metal ions, isotopes, chromogens) color development to detect tissue cell antigens, localization, qualitative and semi-quantitative detection technology" (see 3.1, 3.1 of the.2010 edition);

---Definition "antibody mixture that can react specifically with a certain type of immunogenic substance" is revised to "can recognize different antigenic Clustered Immunoglobulin Molecular Mixtures" (see 3.2.1, 3.2.1 of the.2010 edition);

---In the definition note, "blank control can be non-immune serum or PBS, etc." is revised to "blank control can be non-immune serum, PBS, etc." or non-specific negative control reagents, etc." (see 3.3, 3.3 of the.2010 edition);

--- In the definition, "tissue or cell slice" is changed to "tissue or cell slice" (see 3.4, 3.5, 3.4, 3.5 of the.2010 edition);

---Definition "There are multiple samples with different antigen contents in one slice at the same time, including strong positive tissue control with antigen, weak antigen Positive tissue control and antigen-negative tissue control" was revised to "Multiple tissues or different antigen contents exist simultaneously in one section. samples, including antigen strong positive tissue control, antigen weak positive tissue control and antigen negative tissue control or different expression process degree of tissue control" (see 3.6, 3.6 of the.2010 edition);

---Terms and Definitions "Background under the microscope, is expected to appear outside a specific location of a cell (other cells or intercellular substance)" "Non-specific staining" was changed to "non-specific staining during non-specific staining immunostaining, any non-specific staining Staining resulting from a heteroantigen-antibody reaction is often referred to as "nonspecific staining" (see 3.7, 3.7 of the.2010 edition);

---Definition "Under the microscope, there is obvious color development in the specific position of the expected cells in the positive tissue slice, and no background appears" modification It is defined as "under the microscope, there is significant color development in the specific location of the expected cells in the positive slide, and there is no background staining or non-specificity. Dyeing appears" (see 3.8, 3.8 of the.2010 edition);

---In the classification, "corresponding methods can be divided into immunofluorescence method, radioimmunoassay, immunoenzymatic method and immunogold-silver method, etc." is revised to "corresponding method" Methods can be divided into immunofluorescence, autoradiography, immunoenzymatic, immunoferritin and immunogold and silver" (see 4.2, 4.2 of the.2010 edition);

--- "complete packaging, no damage" is revised to "complete packaging, no damage, no leakage of liquid" [see 5.1b), 5.1b) of the.2010 edition];

--- "Positive control staining result is positive, the location of positive staining should be accurate, no background staining" is modified to "Positive control staining result positive, the location of the positive staining should be accurate, without background staining or non-specific staining" [see 5.2a),.2010 edition of 5.2a)];

--- Logos, labels and instructions for use are changed to "shall comply with the relevant provisions of GB/T 29791.2" (see Chapter 7,.2010 edition of Chapter 7).

1 Scope

This standard specifies the general product classification, requirements, test methods and identification, labels, instructions for use, and packaging of immunohistochemical kits. packaging, transportation and storage.

This standard applies to histochemical/cytochemical qualitative reagents based on antigen-antibody reaction for the detection of human tissue and cell samples, etc. or kit.

2 Normative references

The following documents are essential for the application of this document. For dated references, only the dated version applies to this document. For undated references, the latest edition (including all amendments) applies to this document.

GB/T 191 Graphical signs of packaging, storage and transportation

GB/T 29791.2 Information provided by manufacturers of in vitro diagnostic medical devices (labeling) - Part 2: In vitro diagnostic reagents for professional use

3 Terms and Definitions

The following terms and definitions apply to this document.

3.1 Immunocytochemistry immunocytochemistry; ICC

Using the principle of specific binding between antigens and antibodies, the chromogenic substances (fluorescein, enzymes, metals, etc.) labeled on the antibody are made through chemical reaction.

It is a technique for detecting tissue cell antigens, and for localization, qualitative and semi-quantitative detection.

3.2 Antibody

A specific immunoglobulin that is produced by stimulating B-lymphocytes by immunogenic substances and can bind to immunogenic substances.

NOTE. Molecules of immunogenic substances contain one or more moieties with unique chemical constituents, i.e. epitopes. [YY/T 0639-2019, Definition 3.1]

3.2.1 Polyclonal antibody

A mixture of immunoglobulin molecules capable of recognizing different antigenic determinants. [YY/T 0639-2019, Definition 3.11]

3.2.2 Monoclonal antibody

An antibody that reacts specifically with a single epitope of an immunogenic substance. [YY/T 0639-2019, Definition 3.10]

3.3 Blank control

In immunohistochemistry, a substance that does not contain related antibodies used to replace the primary antibody.

......
This preview omits tables, figures, formulas and parts of the technical clauses. The complete document — 21 pages — is available in the English PDF.

Referenced standards

Editions of YY/T 1181

EditionTitleRevisionStatus
YY/T 1181-2021Immunohistochemistry kitcurrent editionCurrent
YY/T 1181-2010Immunohistochemistry kitprevious editionSuperseded

This page sells the current edition, YY/T 1181-2021. Earlier editions are listed for reference only.

How to Download YY/T 1181-2021

  1. 1

    Add to cart

    Click "Download PDF" on this page and choose "Buy this standard". You can add more standards before checkout.

  2. 2

    Checkout

    Enter your email and billing details. Payment is processed securely by Stripe (cards or bank transfer). Prefer bank details? Request a quotation (min. order $300).

  3. 3

    Fast delivery

    After payment you'll receive an email confirmation. The English PDF is sent to the same address, usually within minutes and at the latest within 1 business day.

  4. 4

    Invoice included

    A tax invoice is attached to the confirmation email. Need a custom invoice? Contact us.

Related Standards

English PDF
21 pages
Fast delivery
Invoice included
View Cart

Secure payment via Stripe

Payments accepted

VisaMastercardAmerican ExpressApple PayGoogle PayStripe

YY/T 1181-2021

$135.00